Insight Pharmaceuticals Acquires e.p.t

Insight Pharmaceuticals, a portfolio company of Swander Pace Capital, has acquired e.p.t, one of the leading brands in home pregnancy testing. e.p.t joins Insight Pharmaceuticals’ family of over-the-counter (OTC) and personal care products that include leading brands such as Sucrets, Nix, Bonine and Gentle Naturals.

“e.p.t aligns well with our strategy to build a significant portfolio of OTC and personal care products by acquiring known and trusted brands that we can leverage through drug, grocery and mass retail channels nationwide,” says Gary R. Downing, CEO, Insight Pharmaceuticals. “This acquisition of e.p.t represents our second major acquisition in the past 18 months.” In June 2009, Insight also acquired a portfolio of well-known brands that includes Gentle Naturals, Dermarest and Pronto Plus.

e.p.t, which stands for “early pregnancy test” and has come to be known as the “error proof test”, pioneered home pregnancy testing as the first FDA-approved, commercially available home pregnancy test, according to the National Institute of Health. Since the 1970s, e.p.t, which is 99 percent percent accurate, has been used by millions of women for early pregnancy detection.

e.p.t will continue to be available through existing retail channels and will be marketed under Insight Pharmaceuticals growing portfolio of products.

“We see tremendous value in the goodwill and brand awareness of e.p.t and our other OTC and personal care products,” says Downing. “We continue to evaluate additional acquisitions to expand our portfolio with quality consumer brands that can be leveraged through our merchandising and marketing expertise.”

HT Capital Advisors acted as exclusive financial advisor to Insight Pharmaceuticals and Swander Pace Capital on this transaction.